Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Absorption and Effects of Patch Test Preparations of Hydroperoxides of Limonene and Hydroperoxides of Linalool in Human Ex Vivo Skin.

Contact dermatitis·2026

Same author

Repeated Exposure to Hydroperoxides of Linalool Induces Immunologically Verified Allergic Contact Dermatitis.

Contact dermatitis·2026

Same author

Synthesis, Computational Studies, and Structural Analysis of 1-(3,5-Dimethoxyphenyl)azetidin-2-ones with Antiproliferative Activity in Breast Cancer and Chemoresistant Colon Cancer.

Pharmaceuticals (Basel, Switzerland)·2025

Same author

Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. <i>Pharmaceuticals</i> 2023, <i>16</i>, 1000.

Pharmaceuticals (Basel, Switzerland)·2025

Same author

Correction: Malebari et al. Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4. <i>Pharmaceuticals</i> 2021, <i>14</i>, 1119.

Pharmaceuticals (Basel, Switzerland)·2025

Same author

Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014-2023).

RSC medicinal chemistry·2025

Search research articles

Related Experiment Video

Updated: Sep 26, 2025

Assessing Specificity of Anticancer Drugs In Vitro

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Special Issue "Anticancer Drugs 2021".

Mary J Meegan¹, Niamh M O'Boyle¹

¹School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse Street, 2 DO2R590 Dublin, Ireland.

Pharmaceuticals (Basel, Switzerland)

|April 23, 2022

Summary

This Special Issue highlights key 2021 advancements in anticancer drug development. It covers novel therapeutic strategies and drug delivery systems for improved cancer treatment outcomes.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Experiment Videos

Last Updated: Sep 26, 2025

Assessing Specificity of Anticancer Drugs In Vitro

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Area of Science:

Oncology
Pharmacology
Drug Discovery

Background:

Anticancer drug development is a dynamic field.
Significant progress was made in 2021.
There is a continuous need for novel therapeutic strategies.

Discussion:

Explores emerging trends in targeted cancer therapies.
Reviews progress in drug delivery systems for enhanced efficacy and reduced toxicity.
Highlights innovative approaches in combination therapies for complex cancers.

Key Insights:

Significant progress in identifying novel molecular targets for cancer intervention.
Development of advanced drug formulations improving pharmacokinetic profiles.
Successful preclinical and clinical outcomes for several new anticancer drug candidates.

Outlook:

Future directions in personalized oncology and precision medicine.
Potential for next-generation anticancer drugs in clinical practice.
The evolving landscape of pharmaceutical research in cancer treatment.